Pharmacokinetics of collagen dipeptides (Gly–Pro and Pro–Hyp) and tripeptides (Gly–Pro–Hyp) in rats

Abstract Although systemic exposure to peptides, such as Gly–Pro–Hyp, Pro–Hyp, and Gly–Pro, has been reported following administration of collagen hydrolysates from fish scale and porcine skin in vivo, the individual peptide pharmacokinetics remain unknown. We administered the three peptides individually to rats via the intravenous (5 mg/kg) and intragastric (100 mg/kg) routes and then monitored systemic exposure and urinary excretion. The peptides in biological samples were analyzed via liquid chromatography/tandem mass spectrometry. Gly–Pro–Hyp tended to exhibit higher first‐pass metabolism than Pro–Hyp; the absolute oral bioavailabilities of Gly–Pro–Hyp and Pro–Hyp were 4.4% and 19.3%, respectively. Gly–Pro levels were very low in the systemic circulation. Pro–Hyp biotransformed from Gly–Pro–Hyp behaved similarly to Pro–Hyp alone when administered orally. Flip‐flop kinetics (elimination rate ≫ absorption rate) were evident, probably reflecting transporter‐mediated slow absorption. A double‐peak phenomenon was observed for Gly–Pro–Hyp and Pro–Hyp when administered orally, and 5.9% ± 2.6% and 1.9% ± 0.3% of each dose were excreted in urine after intravenous administration, respectively. Urinary recovery of Gly–Pro was limited to 0.4% ± 0.5% of the intravenous dose. This work represents the first individual pharmacokinetics of Gly–Pro–Hyp, Pro–Hyp, and Gly–Pro in vivo.